Distinctive exercise-induced inflammatory response and exerkine induction in skeletal muscle of people with type 2 diabetes Visa övriga samt affilieringar
2022 (Engelska) Ingår i: Science Advances, E-ISSN 2375-2548, Vol. 8, nr 36, artikel-id eabo3192Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Mechanistic insights into the molecular events by which exercise enhances the skeletal muscle phenotype are lacking, particularly in the context of type 2 diabetes. Here, we unravel a fundamental role for exercise-responsive cytokines (exerkines) on skeletal muscle development and growth in individuals with normal glucose tolerance or type 2 diabetes. Acute exercise triggered an inflammatory response in skeletal muscle, concomitant with an infiltration of immune cells. These exercise effects were potentiated in type 2 diabetes. In response to contraction or hypoxia, cytokines were mainly produced by endothelial cells and macrophages. The chemokine CXCL12 was induced by hypoxia in endothelial cells, as well as by conditioned medium from contracted myotubes in macrophages. We found that CXCL12 was associated with skeletal muscle remodeling after exercise and differentiation of cultured muscle. Collectively, acute aerobic exercise mounts a noncanonical inflammatory response, with an atypical production of exerkines, which is potentiated in type 2 diabetes.
Ort, förlag, år, upplaga, sidor NLM (Medline) , 2022. Vol. 8, nr 36, artikel-id eabo3192
Nationell ämneskategori
Fysiologi och anatomi
Identifikatorer URN: urn:nbn:se:umu:diva-199460 DOI: 10.1126/sciadv.abo3192 ISI: 000911968500015 PubMedID: 36070371 Scopus ID: 2-s2.0-85137461286 OAI: oai:DiVA.org:umu-199460 DiVA, id: diva2:1698963
Forskningsfinansiär Novo Nordisk, 17OC0030088 Knut och Alice Wallenbergs Stiftelse, 2018.0094 Diabetesfonden, 2018-357 Vetenskapsrådet, 2015-00165 Centrum för Idrottsforskning, P2019-0140 Centrum för Idrottsforskning, P2020-0064 AstraZeneca, 2014-2019 Novo Nordisk, 21SA0072747 Hjärt-Lungfonden, 2017-0669 Hjärt-Lungfonden, 2020-0627 Diabetesfonden, 2018-336 Novo Nordisk, 20SA0064144 2022-09-262022-09-262025-02-10 Bibliografiskt granskad